A phase II study of resection followed capecitabine + oxaliplatin for liver metastasis of colorectal cancer. [REX study]
Phase 2
- Conditions
- iver Metastases of Colorectal Cancer
- Registration Number
- JPRN-UMIN000013324
- Lead Sponsor
- Hyogo College of Medicine, Department of Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Synchronous multiple malignancy (2)Previously treated L-OHP. (3) More than 180days after the last chemotherapy. (4)Pregnant or nursing. (5) Severe peripheral neuropathy. (6) History of severe anaphylaxis or allergia (7)Active infection (8)Severe mental disorder. (9) Severe comorbidity. (10)Systemic steroid user. (11)Patients under treatment with flucytosine,phenytoin,warfarin potassium. (12)Hepatitis B virus infection. (13)Watery diarrhea. (14)Consider not appropriate for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year Disease-Free Survival
- Secondary Outcome Measures
Name Time Method Overall Survival relative dose intensity Adverse events